Mark Zucker, MD
Advanced Heart Failure and Transplant Cardiology · Morristown, NJNPI 1356319180
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,890 of the $44,187 with a category attached, or 67.6%. Merck accounts for 79.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2024 at $26,955 and has fallen 87.1% since, to $3,476 in 2025.
Across 203 payments — averaging $217.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$35K
- Bayer$2K
- Abbott$2K
- Abiomed$1K
- Medtronic$999
- Cvrx, Inc.$738
- plus $3K from 25 others
Across 38 payments — averaging $5452.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$78K
- Pfizer$77K
- Abbott$53K
What the payments were for
- Consulting fees$500%
- Speaking & faculty fees$29,89068%
- Travel & lodging$8,60619%
- Food & beverage$5,54713%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 45 | $34,942 |
| Bayer | 19 | $2,101 |
| Abbott | 17 | $1,801 |
| Abiomed | 6 | $1,026 |
| Medtronic(2 entities) | 9 | $999 |
| Cvrx, Inc. | 7 | $738 |
| Alnylam Pharmaceuticals Inc. | 2 | $447 |
| Impulse Dynamics (USA) Inc. | 6 | $240 |
| E.r. Squibb & Sons, L.L.C. | 12 | $234 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $221 |
| Novartis | 16 | $211 |
| Bridgebio Pharma, Inc. | 3 | $187 |
| AstraZeneca | 6 | $175 |
| Boston Scientific | 2 | $138 |
| Pfizer | 11 | $137 |
| Boehringer Ingelheim | 5 | $98 |
| Amgen | 6 | $81 |
| Scpharmaceuticals Inc. | 2 | $72 |
| Johnson & Johnson | 3 | $47 |
| GSK | 1 | $44 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Sensible Medical Innovations Inc | 1 | $35 |
| Philips North America LLC | 2 | $34 |
| Eurofins Viracor, LLC | 1 | $32 |
| Amarin Pharma, Inc. | 2 | $26 |
| Sobi, Inc | 1 | $17 |
| Kamada Ltd. | 3 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Akcea Therapeutics, Inc. | 1 | $13 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$68,978
- Impella$906
- CardioSight$674
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$503
- HeartMate II LVAS$490
- Barostim Neo System$454
- AMVUTTRA$434
- OPTIMIZER$321
- CARDIOMEMS$270
- HeartMate Touch$181
- Attruby$127
- Kerendia$125
- CAMZYOS$117
- SYNERGY$117
How this compares
$44,187 in reported general payments places this provider in the 75th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
See all advanced heart failure and transplant cardiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 33 | $953,908 |
| CamzyosMavacamten | 30 | $235,297 |
| EntrestoSacubitril/Valsartan | 80 | $95,640 |
| VerquvoVericiguat | 53 | $53,344 |
| EliquisApixaban | 45 | $48,648 |
| JardianceEmpagliflozin | 33 | $45,190 |
| FarxigaDapagliflozin Propanediol | 18 | $23,552 |
| Repatha SureclickEvolocumab | 13 | $11,447 |
| Midodrine Hcl | 39 | $2,139 |
| Digoxin | 11 | $2,040 |
| Ezetimibe | 61 | $2,010 |
| Metoprolol Succinate | 86 | $1,488 |
| Tacrolimus | 16 | $1,348 |
| Carvedilol | 91 | $1,168 |
| Atorvastatin Calcium | 39 | $744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $137 | $1,002,55678 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $234 | $235,29730 claims |
| NovartisEntresto | $211 | $95,64080 claims |
| MerckVerquvo | $34,942 | $53,34453 claims |
| Boehringer IngelheimJardiance | $98 | $45,19033 claims |
| AstraZenecaFarxiga | $175 | $23,55218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
Other advanced heart failure and transplant cardiology in Morristown
- Abhishek SinghMorristown$283K
- Saad AhmadMorristown$74K
- Raul FloresMorristown$11K
- Kanika ModyHackensack$107K
- Kulpreet BarnBarnegat$92K
- Robert MohapatraSewell$84K
- Saurabh KapoorEnglewood$27K
- Ketan GalaCherry Hill$18K
- Ahmed SeliemCamden$8K
- Eman RashedNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.